Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Lymphoma
Interventions
DRUG

bortezomib

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

prednisolone

DRUG

vincristine sulfate

OTHER

questionnaire administration

PROCEDURE

quality-of-life assessment

Trial Locations (25)

RG24 9NA

Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke

B75 7RR

Good Hope Hospital, Birmingham

B9 5SS

Birmingham Heartlands Hospital, Birmingham

FY3 8NR

Blackpool Victoria Hospital, Blackpool

CB2 2QQ

Addenbrooke's Hospital, Cambridge

DA2 8DA

Darent Valley Hospital, Dartford

HG2 7SX

Harrogate District Hospital, Harrogate

LS1 3EX

Leeds General Infirmary, Leeds

L7 8XP

Royal Liverpool University Hospital, Liverpool

SE1 9RT

Guy's Hospital, London

ME16 9QQ

Mid Kent Oncology Centre at Maidstone Hospital, Maidstone

NE1 4LP

Royal Victoria Infirmary, Newcastle upon Tyne

NR31 6LA

James Paget Hospital, Norfolk

NR4 7UY

Norfolk and Norwich University Hospital, Norwich

PL6 8DH

Derriford Hospital, Plymouth

L35 5DR

Whiston Hospital, Prescot Merseyside

SO16 6YD

Southampton General Hospital, Southampton

SR4 7TP

Sunderland Royal Hospital, Sunderland

TA1 5DA

Musgrove Park Hospital, Taunton

TQ2 7AA

Torbay Hospital, Torquay

TR1 3LJ

Royal Cornwall Hospital, Truro, Cornwall

AB25 2ZN

Aberdeen Royal Infirmary, Aberdeen

1V2 3UJ

Raigmore Hospital, Inverness

LL57 2PW

Ysbyty Gwynedd, Bangor

SA14 8QF

Prince Philip Hospital, Llanelli

All Listed Sponsors
lead

University Hospital Plymouth NHS Trust

OTHER

NCT00513955 - Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter